MedTrace Logo

A Study of QLF32101 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

NCT05703204 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2023-01-31

No results posted yet for this study

Summary

This study aimed to evaluate the safety,tolerability and preliminary efficacy of QLF32101 administered intravenously and subcutaneously in patients with R/R, AML.

Conditions

  • Acute Myeloid Leukemia and Myelodysplastic Syndrome

Interventions

DRUG

QLF32101

The dose is given weekly and observed for 28 days(DLT observation period).Single agent treatment.

Sponsors & Collaborators

  • Qilu Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-01
Primary Completion
2024-08-21
Completion
2024-12-21

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05703204 on ClinicalTrials.gov